Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis
Abstract Background Long-term antiviral treatments are associated with a significantly lower hepatocellular carcinoma (HCC) incidence in chronic hepatitis B (CHB) patients by reducing HBV DNA concentrations. However, it is still controversial whether antiviral strategies affect HCC development in an...
প্রধান লেখক: | Ze-Hong Huang, Gui-Yang Lu, Ling-Xian Qiu, Guo-Hua Zhong, Yue Huang, Xing-Mei Yao, Xiao-Hui Liu, Shou-Jie Huang, Ting Wu, Quan Yuan, Ying-Bin Wang, Ying-Ying Su, Jun Zhang, Ning-Shao Xia |
---|---|
বিন্যাস: | প্রবন্ধ |
ভাষা: | English |
প্রকাশিত: |
BMC
2022-03-01
|
মালা: | BMC Cancer |
বিষয়গুলি: | |
অনলাইন ব্যবহার করুন: | https://doi.org/10.1186/s12885-022-09413-7 |
অনুরূপ উপাদানগুলি
অনুরূপ উপাদানগুলি
-
Cost–effectiveness of switching from tenofovir disoproxil fumarate to tenofovir alafenamide versus entecavir for chronic hepatitis B patients in Greece
অনুযায়ী: Emmanouil Sinakos, অন্যান্য
প্রকাশিত: (2024-02-01) -
Real-world single-center experience with entecavir and tenofovir disoproxil fumarate in treatment-naïve and experienced patients with chronic hepatitis B
অনুযায়ী: Young Min Kim, অন্যান্য
প্রকাশিত: (2018-01-01) -
Effects of entecavir and tenofovir disoproxil fumarate on the incidence and severity of COVID-19 in patients with chronic hepatitis B
অনুযায়ী: Xingmei Liao, অন্যান্য
প্রকাশিত: (2023-11-01) -
Effect of entecavir and tenofovir disoproxil fumarate on hepatocellular carcinoma in subjects with chronic hepatitis B: a meta-analysis
অনুযায়ী: Sara M. Tony, অন্যান্য
প্রকাশিত: (2022-09-01) -
Real-World Single-Center Comparison of the Safety and Efficacy of Entecavir, Tenofovir Disoproxil Fumarate, and Tenofovir Alafenamide in Patients with Chronic Hepatitis B
অনুযায়ী: Sara Jeong, অন্যান্য
প্রকাশিত: (2021-11-01)